Fluorescein Injection, USP
- Manufacturer
- Anthea Pharma Private Limited
- Effective date
- 2026-10-14
- Label type
- HUMAN PRESCRIPTION DRUG LABEL
- Version
- 1
- Source
- daily-update
- Hydrated at
- 2026-10-20 03:09:59
Label at a glance#
Label contents#
Full prescribing information#
Product Linked Resources#
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | DataBar Omni | (01)00370710204518 | GTIN-14: 00370710204518 GTIN-12: 370710204518 UPC-A: 370710204518 EAN-13: 0370710204518 GTIN storage (14 digits): 00370710204518 | 5c448a5e-458f-469c-9f1f-417c051b5c15-01.jpg |
Products#
Every source-derived product name is available through these pages.
- FLUORESCEIN
- FLUORESCEIN SODIUM
- HYDROCHLORIC ACID
- SODIUM HYDROXIDE
- WATER
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 83854-048 | 83854-048-01, 83854-048-12 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| FLUORESCEIN SODIUM | 93X55PE38X | ACTIM |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| WATER | 059QF0KO0R | IACT |
Source Document#
Orange Book application contexts#
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218651-001 | FLUORESCEIN SODIUM | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | |
| A218651-002 | FLUORESCEIN SODIUM | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218651-001 | AP |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218651-001 | FLUORESCEIN SODIUM | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | INJECTABLE / INTRAVENOUS | AP | 2026-06-01 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218651-002 | FLUORESCEIN SODIUM | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | INJECTABLE / INTRAVENOUS | RS | 2026-06-01 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218651-001 | AP | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A218651-001 | AP | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A218651-001 | AP | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A218651-001 | AP | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218651-001 | AP | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| FLUORESCEIN | FLUORESCEIN | Anthea Pharma Private Limited | fbf07435-b6c0-49a5-a393-44617e3f451a | 2026-10-14 | 83854-048-01 83854-048-12 83854-048 83854004812 83854004801 5c448a5e-458f-469c-9f1f-417c051b5c15 fbf07435-b6c0-49a5-a393-44617e3f451a |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
